MA32979B1 - Derives aminoesterifies d'alcaloides et composition medicinale les incluant - Google Patents

Derives aminoesterifies d'alcaloides et composition medicinale les incluant

Info

Publication number
MA32979B1
MA32979B1 MA34030A MA34030A MA32979B1 MA 32979 B1 MA32979 B1 MA 32979B1 MA 34030 A MA34030 A MA 34030A MA 34030 A MA34030 A MA 34030A MA 32979 B1 MA32979 B1 MA 32979B1
Authority
MA
Morocco
Prior art keywords
derivatives
alkaloids
aminostrify
pharmaceutical compositions
formulations
Prior art date
Application number
MA34030A
Other languages
Arabic (ar)
English (en)
Inventor
Antonio Caligiuri
Mauro Riccaboni
Gabriele Amari
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40578441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32979(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA32979B1 publication Critical patent/MA32979B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS AMINOESTÉRIFIÉS D'ALCALOÏDES AYANT UN EFFET ANTAGONISTE VIS-À-VIS DES RÉCEPTEURS MUSCARINIQUES, AINSI QUE DES MÉTHODES DE SYNTHÈSE DE TELS DÉRIVÉS, DES COMPOSITIONS LES INCLUANT ET LEURS APPLICATIONS THÉRAPEUTIQUES.
MA34030A 2008-12-23 2009-12-11 Derives aminoesterifies d'alcaloides et composition medicinale les incluant MA32979B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172818A EP2206712A1 (fr) 2008-12-23 2008-12-23 Dérivés d'amino-ester d'alcaloïde et sa composition médicale
PCT/EP2009/008870 WO2010072338A1 (fr) 2008-12-23 2009-12-11 Dérivés aminoestérifiés d'alcaloïdes et composition médicinale les incluant

Publications (1)

Publication Number Publication Date
MA32979B1 true MA32979B1 (fr) 2012-01-02

Family

ID=40578441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34030A MA32979B1 (fr) 2008-12-23 2009-12-11 Derives aminoesterifies d'alcaloides et composition medicinale les incluant

Country Status (24)

Country Link
US (2) US8455646B2 (fr)
EP (2) EP2206712A1 (fr)
JP (1) JP2012513420A (fr)
KR (1) KR101414333B1 (fr)
CN (1) CN102264734B (fr)
AR (1) AR074855A1 (fr)
AU (1) AU2009331945A1 (fr)
BR (1) BRPI0918206A2 (fr)
CA (1) CA2748100A1 (fr)
CO (1) CO6400144A2 (fr)
EA (1) EA020974B1 (fr)
GE (1) GEP20146154B (fr)
IL (1) IL213712A0 (fr)
MA (1) MA32979B1 (fr)
ME (1) ME01185B (fr)
MX (1) MX2011006642A (fr)
MY (1) MY150823A (fr)
NZ (1) NZ593695A (fr)
PE (1) PE20110829A1 (fr)
SG (1) SG172316A1 (fr)
TN (1) TN2011000282A1 (fr)
TW (1) TW201028412A (fr)
UA (1) UA107334C2 (fr)
WO (1) WO2010072338A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2154136A1 (fr) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Dérivés de carbone de quinuclidine et ses compositions médicales
EP2206712A1 (fr) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. Dérivés d'amino-ester d'alcaloïde et sa composition médicale
KR20130111968A (ko) * 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
CA2803459A1 (fr) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Derives aminoester d'alcaloides et compositions medicinales les comprenant
WO2011160919A1 (fr) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dérivés aminoester d'alkaloïdes et composition médicinale les comprenant
KR20130141534A (ko) * 2010-11-26 2013-12-26 키에시 파르마슈티시 엣스. 피. 에이. 글리신 유도체 및 무스카린 수용체 길항제로서의 이들의 용도
US20120220557A1 (en) * 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
RU2611627C2 (ru) * 2011-04-29 2017-02-28 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Алкалоидный эфир и карбаматные производные и их медицинские композиции
KR20140105746A (ko) 2011-12-30 2014-09-02 키에시 파르마슈티시 엣스. 피. 에이. 항무스카린제로서 1-아자헤테로시클릴아세트산의 퀴누클리딘 에스터, 이들의 제조 방법 및 이들의 의약 조성물
HU230368B1 (hu) 2012-11-16 2016-03-29 Magyar Tudományos Akadémia Szegedi Biológiai Kutatóközpont Új módszer az emlős mesterséges kromoszóma több génnel való feltöltésére
US9427376B2 (en) 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CA2966005C (fr) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anticorps anti-cs1 et conjugues anticorps-medicament
CN104876854B (zh) * 2015-04-16 2017-03-01 御盛隆堂药业有限责任公司 羟基乙酸酯衍生物及其用途
WO2018211530A1 (fr) 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research Méthanopyrido [2, 1-a] isoindolones substituées utilisées en tant que modulateurs de machr pour traiter diverses conditions pathophysiologiques associées et leur procédé de préparation
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Ｔｙｋ２抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2824106A (en) * 1958-02-18 Quaternary tropeine compounds and a process of making same
US2856407A (en) * 1956-08-08 1958-10-14 Lakeside Lab Inc Aminoacid esters of n-substituted 3 and 4-piperidinols
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
IT1255323B (it) * 1992-07-08 1995-10-31 Fidia Spa Composti ad attivita' analgesica e nootropa
AU685225B2 (en) * 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
JP4238334B2 (ja) * 1996-09-10 2009-03-18 ヴァーナリス （アールアンドディー） リミテッド 細胞増殖抑制性ヒドロキサム酸誘導体
US6410539B1 (en) * 1997-10-22 2002-06-25 Astrazenca Uk Limited Imidazole derivatives and their use as farnesyl protein transferase inhibitors
EP1345937B1 (fr) * 2000-12-22 2005-09-28 Almirall Prodesfarma AG Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
CA2470956C (fr) 2001-12-20 2011-08-02 Laboratorios S.A.L.V.A.T., S.A. Derives de 1-alkyl-1- azoniabicyclo[2.2.2]octane carbamate
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1882691A1 (fr) 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Dérivés de quinuclidine comme antagonistes M3
GB0621830D0 (en) * 2006-11-02 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
KR20090094460A (ko) * 2006-12-19 2009-09-07 아스트라제네카 아베 무스카린 수용체 길항제로서 퀴누클리디놀 유도체
WO2008075006A1 (fr) * 2006-12-19 2008-06-26 Astrazeneca Ab Composés de piperldinum pour le traitement de maladies pulmonaires obstructives
EP2154136A1 (fr) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Dérivés de carbone de quinuclidine et ses compositions médicales
EP2206712A1 (fr) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. Dérivés d'amino-ester d'alcaloïde et sa composition médicale
CA2803418A1 (fr) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Formulation de poudre seche comprenant un medicament antimuscarinique
CA2803459A1 (fr) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Derives aminoester d'alcaloides et compositions medicinales les comprenant
KR20130111968A (ko) 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
WO2011160919A1 (fr) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dérivés aminoester d'alkaloïdes et composition médicinale les comprenant
CN103168038A (zh) 2010-10-20 2013-06-19 奇斯药制品公司 用于治疗咳嗽的碳酸酯衍生物
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
RU2611627C2 (ru) 2011-04-29 2017-02-28 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Алкалоидный эфир и карбаматные производные и их медицинские композиции

Also Published As

Publication number Publication date
KR20110097883A (ko) 2011-08-31
KR101414333B1 (ko) 2014-07-02
WO2010072338A1 (fr) 2010-07-01
US8835682B2 (en) 2014-09-16
CO6400144A2 (es) 2012-03-15
US20100173880A1 (en) 2010-07-08
SG172316A1 (en) 2011-07-28
TW201028412A (en) 2010-08-01
MY150823A (en) 2014-02-28
EA201190017A1 (ru) 2012-02-28
UA107334C2 (ru) 2014-12-25
BRPI0918206A2 (pt) 2015-12-08
PE20110829A1 (es) 2011-11-19
EP2376489A1 (fr) 2011-10-19
JP2012513420A (ja) 2012-06-14
TN2011000282A1 (en) 2012-12-17
CN102264734B (zh) 2015-06-17
CA2748100A1 (fr) 2010-07-01
US8455646B2 (en) 2013-06-04
US20130196978A1 (en) 2013-08-01
EP2376489B1 (fr) 2015-04-22
EA020974B1 (ru) 2015-03-31
EP2206712A1 (fr) 2010-07-14
AU2009331945A1 (en) 2011-07-14
HK1162174A1 (en) 2012-08-24
IL213712A0 (en) 2011-07-31
NZ593695A (en) 2014-01-31
GEP20146154B (en) 2014-09-10
ME01185B (fr) 2013-03-20
MX2011006642A (es) 2011-07-29
AR074855A1 (es) 2011-02-16
CN102264734A (zh) 2011-11-30

Similar Documents

Publication Publication Date Title
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
BR112012018345A2 (pt) &#34;compostos de heteroarila, bem como composições e usos dos mesmos&#34;
HK1203309A1 (zh) 抗體-藥物綴合物以及相關化合物、組合物和方法
MA32383B1 (fr) DÉRIVÉS D&#39;INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
BRPI0915084B8 (pt) composto, e, composição farmacêutica
BRPI0914682B8 (pt) compostos de heteroarila e composições compreendendo os referidos compostos
EA201170832A1 (ru) Пуриновые соединения
CR11861A (es) Compuestos organicos
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
ATE502921T1 (de) Substituierte indole
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
MX395271B (es) Composicion farmaceutica.
MA32508B1 (fr) Composes organiques
EA201170884A1 (ru) Производные пиперидина, пригодные в качестве антагонистов орексина
EA201070519A1 (ru) Соединения тропана
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
MA32776B1 (fr) Inhibiteurs de l&#39;akt et de la p70 s6 kinase
EA201170227A1 (ru) Имидазолкарбоксамиды
BR112012011328A2 (pt) inibidores de akt
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon